IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection

Table 6 Stratified analyses of rs303218 and virological response

Variables	No./total1	rs303218
		OR	95%CI	P value2
Age (yr)
≤ 26	39/117	0.79	0.42-1.48	0.453
> 26	44/108	0.59	0.33-1.04	0.070
Gender
Male	55/163	0.53	0.32-0.88	0.0133
Female	28/62	1.03	0.46-2.31	0.947
Baseline ALT
≤ 150	38/113	0.38	0.20-0.74	0.0033
> 150	45/112	0.91	0.52-1.60	0.734
Baseline AST
≤ 83	34/114	0.31	0.16-0.61	0.0013
> 83	49/111	1.10	0.62-1.96	0.752
Baseline HBV DNA copies (log10 IU/mL)
≤ 7.36	47/113	0.86	0.49-1.52	0.611
> 7.36	36/112	0.47	0.25-0.88	0.0183
HBV genotype
Type B	42/94	0.74	0.42-1.31	0.304
Type C	10/15	2.19	0.36-13.51	0.397
Type B + C	22/80	0.41	0.19-0.86	0.0183

¹Number indicated the patients who responsed in the same group;

²P value was calculated by logistic regression analysis with adjustment of patient characteristics with P < 0.05 in univariate analysis in additive model (the adjusting covariate for virological response was HBV genotype);

³P < 0.05. ALT: Alanine aminotransferase; AST: Aspartate transaminase; HBV: Hepatitis B virus.